Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IMVT,391480000,97971200,18615000,,-28237000,,-28158000,10302000,0,-28917000,-28917000,,,,,,-79000,0,28917000,0,680000,,-28158000,-28158000,590425000,21009000,391480000,412489000,10000,-198657000,-298000,400146000,18771000,-298000,3483000,409006000,548000,2432000,337000.0,-95000.0,763000.0,428000.0,763000.0,-21828000.0,-22496000.0,22000.0,4942000.0,-95000.0,,,390235000,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,-0.31982666,0,PRE,NMS,False,False,8.82,1630526403,0.15999985,8.7,8.92,8.61,729538,15,America/New_York,EDT,2,1.8475734,8.61 - 8.92,8.66,0.0,0.0,22,22,finmb_592774643,NasdaqGS,"Immunovant, Inc.",USD,1315160,841000,2.1399999,0.32035926,6.68 - 53.75,-44.93,-0.835907,6.68,53.75,1613482200,1613482200,1613482200,-1.57,-5.617834,-14400000,8.761143,0.058856964,0.006717955,12.967282,-4.1472826,864105984,"Immunovant, Inc.",,,,53.75,6.68,8.76,12.97,1.32M,841k,97.97M,,35.14M,61.01%,41.57%,5.38M,2.62,12.95%,5.50%,6.42M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",0.00%,0.00%,-25.90%,-44.25%,,,,,-108.05M,-107.43M,,,400.15M,4.08,3.42M,0.87,21.79,,-83.33M,-43.79M,Value,10018,Healthcare,68,10,7,"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.",New York,917 580 3099,NY,10,1609372800,1622505600,10,United States,http://immunovant.com,86400,10,320 West 37th Street,Biotechnology
t-1,IMVT,414152000,97971200,21091000,,-32143000,,-31776000,10549000,0,-31640000,-31640000,,,,,,-367000,0,31640000,0,-503000,,-31776000,-31776000,584174000,18877000,414152000,433029000,10000,-170499000,467000,421974000,16485000,467000,3601000,429428000,481000,2100000,-3823000.0,-29000.0,446000.0,6242000.0,841000.0,-22398000.0,-22815000.0,19000.0,6964000.0,-29000.0,-134000.0,-261000.0,412943000,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,-0.31982666,0,PRE,NMS,False,False,8.82,1630526403,0.15999985,8.7,8.92,8.61,729538,15,America/New_York,EDT,2,1.8475734,8.61 - 8.92,8.66,0.0,0.0,22,22,finmb_592774643,NasdaqGS,"Immunovant, Inc.",USD,1315160,841000,2.1399999,0.32035926,6.68 - 53.75,-44.93,-0.835907,6.68,53.75,1613482200,1613482200,1613482200,-1.57,-5.617834,-14400000,8.761143,0.058856964,0.006717955,12.967282,-4.1472826,864105984,"Immunovant, Inc.",,,,53.75,6.68,8.76,12.97,1.32M,841k,97.97M,,35.14M,61.01%,41.57%,5.38M,2.62,12.95%,5.50%,6.42M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",0.00%,0.00%,-25.90%,-44.25%,,,,,-108.05M,-107.43M,,,400.15M,4.08,3.42M,0.87,21.79,,-83.33M,-43.79M,Value,10018,Healthcare,68,10,7,"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.",New York,917 580 3099,NY,10,1609372800,1622505600,10,United States,http://immunovant.com,86400,10,320 West 37th Street,Biotechnology
t-2,IMVT,438406000,97971200,11976000,,-20749000,,-20789000,8998000,0,-20974000,-20974000,,,,,,40000,0,20974000,0,225000,,-20789000,-20789000,577341000,15489000,438406000,453895000,10000,-138723000,-222000,444372000,12810000,-222000,3629000,450266000,40000,5787000,-2074000.0,-39000.0,188350000.0,-4761000.0,188925000.0,164093000.0,-24218000.0,14000.0,3408000.0,-39000.0,-202000.0,-373000.0,437456000,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,-0.31982666,0,PRE,NMS,False,False,8.82,1630526403,0.15999985,8.7,8.92,8.61,729538,15,America/New_York,EDT,2,1.8475734,8.61 - 8.92,8.66,0.0,0.0,22,22,finmb_592774643,NasdaqGS,"Immunovant, Inc.",USD,1315160,841000,2.1399999,0.32035926,6.68 - 53.75,-44.93,-0.835907,6.68,53.75,1613482200,1613482200,1613482200,-1.57,-5.617834,-14400000,8.761143,0.058856964,0.006717955,12.967282,-4.1472826,864105984,"Immunovant, Inc.",,,,53.75,6.68,8.76,12.97,1.32M,841k,97.97M,,35.14M,61.01%,41.57%,5.38M,2.62,12.95%,5.50%,6.42M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",0.00%,0.00%,-25.90%,-44.25%,,,,,-108.05M,-107.43M,,,400.15M,4.08,3.42M,0.87,21.79,,-83.33M,-43.79M,Value,10018,Healthcare,68,10,7,"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.",New York,917 580 3099,NY,10,1609372800,1622505600,10,United States,http://immunovant.com,86400,10,320 West 37th Street,Biotechnology
t-3,IMVT,267775000,97971200,16922000,,-26660000,,-26708000,9664000,0,-26586000,-26586000,,,,,,48000,0,26586000,0,-74000,,-26708000,-26708000,385691000,22516000,267775000,290291000,8000,-117934000,10000,280279000,19544000,10000,4175000,286116000,24000,8011000,6811000.0,-47000.0,193553000.0,1918000.0,197009000.0,179708000.0,-13798000.0,10000.0,4159000.0,-47000.0,-2854000.0,-602000.0,266572000,en-US,US,EQUITY,True,Delayed Quote,us_market,USD,-0.31982666,0,PRE,NMS,False,False,8.82,1630526403,0.15999985,8.7,8.92,8.61,729538,15,America/New_York,EDT,2,1.8475734,8.61 - 8.92,8.66,0.0,0.0,22,22,finmb_592774643,NasdaqGS,"Immunovant, Inc.",USD,1315160,841000,2.1399999,0.32035926,6.68 - 53.75,-44.93,-0.835907,6.68,53.75,1613482200,1613482200,1613482200,-1.57,-5.617834,-14400000,8.761143,0.058856964,0.006717955,12.967282,-4.1472826,864105984,"Immunovant, Inc.",,,,53.75,6.68,8.76,12.97,1.32M,841k,97.97M,,35.14M,61.01%,41.57%,5.38M,2.62,12.95%,5.50%,6.42M,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",0.00%,0.00%,-25.90%,-44.25%,,,,,-108.05M,-107.43M,,,400.15M,4.08,3.42M,0.87,21.79,,-83.33M,-43.79M,Value,10018,Healthcare,68,10,7,"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.",New York,917 580 3099,NY,10,1609372800,1622505600,10,United States,http://immunovant.com,86400,10,320 West 37th Street,Biotechnology
